CTOs on the Move

Crinetics

www.crinetics.com

 
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company`s lead product candidate, paltusotine (formerly CRN00808), is an investigational, oral, selective nonpeptide somatostatin receptor type 2 biased agonist for the treatment of acromegaly, an orphan disease affecting more than 26,000 people in the United States. A Phase 3 program in acromegaly with paltusotine is underway. Crinetics also plans to advance paltusotine into a Phase 2 trial for the treatment of carcinoid syndrome associated with neuroendocrine tumors. The company is also developing CRN04777, an ...
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.crinetics.com
  • 10222 Barnes Canyon Road Building 2
    San Diego, CA USA 92121
  • Phone: 858.450.6464

Executives

Name Title Contact Details

Funding

Crinetics raised $40M on 11/02/2015

Similar Companies

BioPharm Engineered Systems

BioPharm Engineered Systems is a Andover, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amer Assoc of Electrodiagnostic Medicine

Amer Assoc of Electrodiagnostic Medicine is a Rochester, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ionpath

Ionpath delivers high definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate discovery and improve human health. Ionpath`s MIBI™ (multiplexed ion beam imaging) Platform breaks through the limitations of traditional IHC, enabling deep understanding of the tissue microenvironment with highly multiplexed quantitative single-cell analysis.

Lyndra

Lyndra Therapeutics is pioneering the first-ever oral, ultra-long-acting, sustained release therapies, which have the potential to fundamentally change the way people take medicine by enabling patients to take a pill once a week rather than daily. The Company`s breakthrough Extended-Release Oral Capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something no oral therapy has ever achieved before. Lyndra`s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a significant driver of outcomes, including schizophrenia and other central nervous system diseases, diabetes, cardiovascular disease and opioid abuse disorder, among others. The Company is also committed to advancing its platform across new chemical entities and a variety of critical global and public health opportunities alongside partners such as the Bill & Melinda Gates Foundation and the NIH.

Swing Therapeutics

Swing Therapeutics was founded in 2019 with the goal of developing digital treatments in disease areas where patients are not well-served, and where digital interventions may be effective.